Earnings Preview: Pacific Biosciences
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.28. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historically, the company's share price has reacted variably to past earnings reports, with a notable 13.08% drop after last quarter's beat. Over the last year, PACB shares have declined by 40.83%, indicating a bearish sentiment among long-term shareholders.
February 14, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacific Biosciences is expected to report an EPS of $-0.28 for the upcoming quarter. Historical data shows mixed stock price reactions to earnings reports, with a significant 13.08% drop after the last quarter's beat. Shares have fallen 40.83% over the past year.
The expected EPS and historical performance suggest a cautious outlook for PACB's short-term stock price movement. The significant drop after the last quarter's earnings beat and the overall yearly decline indicate potential volatility around the earnings report. However, the actual impact will heavily depend on whether the company meets or exceeds the EPS estimate and the nature of the guidance provided.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100